50 of the Top 250 law firms use our Products every day
|
EXHIBIT 10.1
EXCLUSIVE
RIGHT TO LICENSE AGREEMENT
Oncolin Therapeutics, Inc. of Houston, Texas would
like to evaluate Genistein analogs and the Pharmaceutical
Research Institute ( PRI ) and Dr. Janusz Obukowicz would
like to have the same analogs evaluated and therefore agree
to the following terms:
1. Oncolin
Therapeutics will have an exclusive worldwide right to
license patents and patent applications covering composition
and/or use of Genistein analogs for cancer treatment for a
period of 9 months from receipt of compounds to be tested at
$4,000.00/patent. If the company requires additional time ,
Oncolin would pay an additional $8,000/patent for a 6 month
extension.
2. PRI
will supply 1-2 of its best compounds for evaluation
initially providing 100 mg quantities for in vitro evaluation
and gram quantities of 1-2 compounds for in vivo evaluation
for a small fee not to exceed $5,000. The results of these
experiments will be provided to PRI.
3. If
Oncolin desires to licen
|
